Showing 696 results
-
Media Release /Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1…
-
Media Release /New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx® data build on extensive body of…
-
Media Release /Cosentyx is the only IL‑17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty,…
-
Media Release /Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands…
-
Media Release /In the real-world, Pluvicto® showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI…
-
Media Release /Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment…
-
Media Release /Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a highly selective oral BTK inhibitor, was well-…
-
Media Release /In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1 Results favored Vanrafia across multiple…
-
Media Release /New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,…
-
Media Release /NFL Icons Coach Bruce Arians, Rob Gronkowski, George Kittle and more partner with Novartis to prioritize early prostate cancer detection One in eight men will face prostate cancer1, yet…
